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ABBREVIATIONS PAGE 
3’UTR, 3 prime untranslated region of mRNA 
5’UTR, 5 prime untranslated region of mRNA 
αSMA, α smooth muscle actin 
CAD, chronic allograft dysfunction  
CD31, platelet endothelial cell adhesion molecule (PECAM1) 
CTGF, connective tissue growth factor 
DPP-4, dipeptidyl peptidase 4 
EndMT, endothelial-to-mesenchymal transition 
eNOS, endothelial nitric oxide synthase 
EPC, bone marrow derived endothelial progenitor cells 
ER stress, endoplasmic reticular stress 
ERK, extracellular signal regulated kinase 
ET-1, Endothelin-1 
FGF, fibroblast growth factor 
FGFR, fibroblast growth factor receptor 
FRS2α, fibroblast growth factor receptor subunit 2α 
GFR, glomerular filtration rate 
GRB2, growth factor receptor bound protein 
GTP, guanosine triphosphate 
HAEC, human aortic endothelial cells 
HAVEC, human aortic valve endothelial cells 
HCAEC, human coronary artery endothelial cells 
HCV, hepatitis C virus 
HIF-1α, hypoxia inducible factor-1α 
HMVEC, human dermal microvascular endothelial cells 
HUAEC, human umbilical artery endothelial cells 
HUVEC, human umbilical vein endothelial cells 
IL1β, interleukin 1β 
INFϒ, interferon γ 
KLF, krüppel-like factor 
MALAT, metastasis associated lung adenocarcinoma transcript 1 
MEEC, mouse embryonic endothelial cells 
miRNA, mature microRNA 
MMP, matrix metalloproteinase 
mRNA, messenger RNA 
NECD, notch extracellular domain 
NICD, notch intracellular domain 
NOX, NADPH oxidases 
PAI-1, plasminogen activator inhibitor-1, also called CD31 
p-Akt, phosphorylated Akt 
PI3K, phosphoinositide 3-kinase 
Pri-miRNA, primary transcript of microRNA 
PTEN, phosphatase and tensin homolog 
RNA, ribonucleic acid 
HPEC, human pulmonary endothelial cells 
ROCK, rho-associated protein kinase  
ROS, reactive oxygen species 
SARA, Smad anchor for receptor activation 
TAC, transverse aortic constriction 
TGFβ, transforming growth factor β 
TGFβR, transforming growth factor β receptor 
TNFα, tumour necrosis factor α 
Abstract 
Fibrosis is a universal finding in chronic allograft dysfunction and is characterized by 
an accumulation of extracellular matrix. The precise source of the myofibroblasts 
responsible for matrix deposition is not understood and pharmacological strategies 
for prevention or treatment of fibrosis remain limited. One source of myofibroblasts in 
fibrosis is EndMT, a process first described in heart development. Recently, lineage 
tracing of endothelial cells in mouse models allowed studies of EndMT in vivo and 
reported 27-35% of myofibroblasts involved in cardiac fibrosis and 16% of isolated 
fibroblasts in bleomycin-induced pulmonary fibrosis to be of endothelial origin. 
Over the last decade, microRNAs have increasingly been described as key 
regulators of biological processes through repression or degradation of targeted 
mRNA. The stability and abundance of microRNAs in body fluids makes them 
attractive as potential biomarkers and progress is being made in developing 
microRNA targeted therapeutics.  
In this review we will discuss evidence of microRNA regulation of EndMT from in 
vitro and in vivo studies and the potential relevance of this to heart, lung and kidney 
allograft dysfunction. 
Introduction 
Organ transplantation is the gold standard and in many cases the only treatment for 
patients with end-stage organ failure.1 A limitation to successful transplantation is 
CAD where one of the processes leading failure of the transplanted organ is 
fibrosis.2-4 Increasing graft survival remains a challenge; over the last two decades 
there have been substantial improvements in short-term outcomes after 
transplantation, but a reduction in late graft failure has been harder to achieve.1,4,5  
Although fibrosis is common, fundamental questions about the mechanisms of 
fibrosis remain, including the origins of matrix producing myofibroblasts. EndMT is 
the process by which endothelial cells undergo a phenotypic change to become 
more like mesenchymal cells. The transition may be partial and reversible but in 
undergoing EndMT endothelial cells loose markers such as CD31 and VE-cadherin 
and gain mesenchymal ones including αSMA. Cell adhesion properties are lost and 
morphology changes from a closely abutting cobblestone pattern to elongated cells 
with increased potential for migration, therefore resembling myofibroblasts.6-9  
MicroRNAs have been shown to be regulators of many cellular processes10 and the 
purpose of this review is to examine the current evidence on their regulation of 
endothelial cell phenotype in fibrosis of heart, lung and kidney. Better understanding 
of this process could lead to new therapies to reduce fibrosis in allografts and 
therefore increase graft survival. 
Origin of myofibroblasts 
Myofibroblasts have been shown to be the key effector cells in fibrosis and whilst it is 
agreed they have multiple sources, their exact origins remain unclear and may vary 
with tissue type.6,7,9,11-13 The current candidates are shown in Figure 1. 
Using endothelial cell lineage tracing and double-labelling techniques in mouse 
models of cardiac and renal fibrosis, approximately 30% of all fibroblasts were found 
to be of endothelial origin.14 Conversely, lineage tracing in an ischaemic model of 
cardiac fibrosis found <1% of myofibroblasts to be of endothelial origin.15 This 
discrepancy may relate to the models of fibrosis and markers used. 
Studies in pulmonary fibrosis models have provided further evidence of EndMT; co-
localisation of αSMA with an endothelial marker has been demonstrated16,17 and 
lineage tracing in bleomycin-induced pulmonary fibrosis identified 16% of isolated 
fibroblasts to be of endothelial origin.18 
Staining on human allografts undergoing rejection have also provided evidence for 
the process of EndMT in these tissues. Compared to healthy controls, kidneys from 
patients diagnosed with CAD show increased expression of mesenchymal markers 
and a decreased expression of endothelial markers. Furthermore, double-staining 
found colocalisation of endothelial and mesenchymal markers in the CAD group 
providing further support for the role of EndMT in renal CAD.19  
Similarly, in tissue from human cardiac allografts that had undergone rejection, the 
presence of EndMT has been suggested by a loss of FGFR1 staining and a gain in 
phosphorylated Smad2 when compared to controls.20 Furthermore, in luminal 
endothelial cells colocalisation of CD31 with mesenchymal marker Notch3 was 
significantly greater in human coronary arteries from chronically rejecting heart 
allografts (evident in 80% of cases) when compared to normal human coronary 
arteries.21  
Mechanism of EndMT in fibrosis 
The cell signalling mechanisms that control EndMT are covered in detail 
elsewhere.7,9 In brief, TGFβ signalling is the most clearly defined but several other 
pathways have been shown to be involved, a summary of which is provided in Figure 
2.  
Downstream of TGFβ signalling the Smad proteins are key effectors of changes in 
gene expression along with other transcriptional regulators such as Snail, Twist and 
Slug.7 SARA gives Smads access to TGFβ to enable phosphorylation of Smad2 and 
Smad3 which then join Smad4 to alter gene expression.22 
A parallel pathway downstream of TGFβ involves GRB2. GRB2 is bound to the 
TGFβ receptor and converts Ras to its active GTP-bound form that affects ROCK 
and RhoA-GTP activity downstream to modulate gene expression.23  
Other pathways have also been found to interact with TGFβ signalling. ET-1 acts 
synergistically with TGFβ but cannot induce EndMT alone whereas PAI-1 inhibits 
TGFβ signalling.24-26 There is a reciprocal inhibitory interaction between FGF signalling 
(via FGFR1 and its intracellular subunit FRS2α) and TGFβ signalling. Inflammatory 
cytokines IL1β, TNFα and INFϒ promote TGFβ indirectly through inhibition of FGF 
signalling.9,20,21,27  
The Mitogen Activated Protein Kinase/ERK branch of the signalling cascade has been 
shown to be modulated during EndMT but may not be an essential element.28 PI3K 
activity is affected by fibrotic stimuli but the response seen in EndMT is not consistent 
between studies and the impact of phosphorylated Akt levels on gene expression is 
not fully understood.7,9,29-31  
Notch signalling, ER stress, ROS and hypoxia have also been found to impact on 
EndMT . The Notch signalling cascade has increased activity in EndMT with NICD 
separating from NECD to affect gene expression directly or via the transcription factor 
Hey-1.32 ER stress causes a reduction in hydrogen sulfide (H2S) to affect gene 
expression.33 ROS are generated from increased NOX and increase NFκB availability 
to alter gene expression.34 Hypoxia activates HIF-1α which in turn affects gene 
expression either directly or via the transcription factor Snail1 whose levels also 
increase downstream of TGFβ through inhibition of its proteasomal degradation.35 
How microRNAs work 
MicroRNAs are short single-stranded non-coding RNA sequences around 22 
nucleotides in length that regulate protein expression at the post-transcriptional 
level.10,36 Given >60% of protein coding genes are thought to be under microRNA 
control,10 these RNA sequences likely play a role in regulating almost every cellular 
process and there is increasing evidence for their involvement in fibrosis and 
EndMT.7,37 
Mature, single-stranded microRNAs are produced by processing of their double-
stranded precursors (Figure 3). Nucleotides 2-8 of the miRNA are referred to as the 
seed region and bind the target sequence on mRNA through Watson-Crick pairing to 
direct the miRNA-induced silencing complex. Predominantly, it is the 3’UTR of target 
mRNA to which the seed region binds but less frequently target sequences have 
also been identified in the open reading frame and the 5’UTR of mRNA.38,39 
Infrequently miRNAs have been associated with increased protein expression; this 
may be through inhibition of repressors or direct stimulation of mRNA translation.39 
Evidence of microRNA involvement in EndMT in heart, lung and kidney 
fibrosis 
In vitro studies 
EndMT has been demonstrated in vitro on exposure of endothelial cells to fibrotic 
stimuli such as TGFβ 28,40,41 high glucose concentrations,42,43 radiation44 or 
hypoxia.35,45 MicroRNA arrays have been used to screen for differentially expressed 
miRNAs in the presence or absence of fibrotic stimuli.28,42,45 A summary of miRNAs 
whose levels have been found to be affected in EndMT is shown in Table 1.  
A role in activating EndMT has been suggested for certain miRNAs as blocking them 
is effective in preventing the process. MiR-21 is expressed at higher levels in human 
cardiac fibroblasts than in endothelial cells and is upregulated in response to TGFβ 
stimulation in HUVEC.34,46 MiR-21 blockade partly rescues endothelial marker 
expression that was suppressed by TGFβ in these cells and prevents changes in 
gene expression associated with EndMT.46 Furthermore, exposure to miR-21 directly 
stimulated EndMT in the absence of TGFβ. In HPECs however, although miR-21 
was upregulated it was found to be dispensable in EndMT occurring in response to 
radiation as its inhibition did not affect this process.44 In human lung fibroblasts miR-
21 expression increased and a miR-21 antagomir inhibited expression of collagen 
type IIIA supporting involvement in fibrosis although not necessarily in EndMT.44 
Upregulating other miRNAs can prevent EndMT indicating that they function as 
inhibitors of this process with their downregulation being required to allow EndMT. 
For instance, in high glucose conditions, miR-18a-5p47, miR-200b43 and miR-32042 
are downregulated and their upregulation appears to protect against EndMT and 
maintain normal endothelial function 
In the case of miR-200a, which has been shown to oppose EndMT, overexpression 
can increase endothelial marker expression above baseline in the absence of 
TGFβ.23 Other miRNAs appear to have a more purely regulatory role rather than 
being capable of stimulating a change.22 
Serum from patients with fibrotic disease has been shown to modulate miRNA 
levels. Incubating HUVEC with serum from patients with Kawasaki disease  was 
associated with lower expression of miR-483 when compared with cells incubated 
with healthy sera. Overexpression of miR-483 attenuated the EndMT response to 
diseased sera.48 
Certain upregulated miRNAs may play a role in negative feedback within the 
signalling pathway for EndMT. Although miR-155 is upregulated under fibrotic 
conditions, TGFβ stimulation and hypoxia, overexpression with pre-miR-155 blocks 
the ability of TGFβ to induce EndMT in mouse embryonic endothelial cells. In 
support of an inhibitory role, antagomirs to miR-155 were able to induce αSMA 
expression in the absence of TGFβ.45 
Pre-clinical models 
As with in vitro studies, microRNA array data on animal tissue has also 
demonstrated differential expression of certain miRNAs between organs that have 
undergone fibrosis in response to transplantation, radiation,44 chronic hypoxia31 or 
diabetes27  and control uninjured tissues. Although this does not necessarily indicate 
involvement in the process of EndMT, it can help to focus the direction of further 
studies.27,31,44 Table 2 shows changes in miRNA expression identified in different 
models of fibrosis.  
Changes in expression observed in vitro do not consistently translate to in vivo 
models (Table 1). Although TGFβ treatment was associated with downregulation of 
miR-29b and upregulation of miR-216a in HUVEC, these changes were not seen in 
endothelial cells sorted from hearts of TAC operated mice when compared to sham-
operated controls. There was, however, evidence of EndMT occurring in these 
hearts.46 
Involvement of miRNA in the process of EndMT in vivo has been suggested through 
correlation between expression of specific miRNAs, extent of EndMT and amount of 
fibrosis in the studied tissues. For instance, the CD1 strain of mice experience more 
renal fibrosis in response to diabetes than 129Sv mice. The mechanism of fibrosis in 
CD1 mice is at least partially driven by EndMT as demonstrated by increased 
colocalisation of endothelial and mesenchymal markers in diabetic kidneys vs 
controls. This pattern was seen to a much lesser extent in 129Sv mice. Interestingly, 
in CD1 mice but not in 129Sv mice, diabetes was associated with suppression of let-
7 and miR-29 in the kidney.27  
Consistent with the finding that miR-21 promotes EndMT in vitro46, miR-21 levels 
were found to be increased compared to controls in lung tissue from a mouse model 
of radiation-induced pulmonary fibrosis. In situ hybridisation showed this increase to 
be specific to radiation-damaged areas of lung. As the presence of EndMT in vivo 
was not investigated, a direct effect of miRNA on EndMT could not be 
demonstrated.44 
The impact of specific miRNAs on the process of EndMT has been investigated in 
vivo through manipulation of their levels. An inhibitory effect of let-7 on EndMT was 
supported by the increased expression of mesenchymal markers in endothelial cells, 
associated with administering let-7 antagomirs in adult mice.21 This role was further 
examined using a transplant model of aorta allograft in transgenic mice that allow 
fate mapping of endothelial cells by labelling with green fluorescent protein. Tissue 
was examined 2 weeks after transplantation, when rejection was occurring.I In mice 
given let-7 antagomirs the proportion of luminal endothelial cells undergoing EndMT 
had increased from 61% to 80-90%. Conversely, let-7 mimic reduced collagen 
deposition and the proportion of endothelial cells undergoing EndMT to 33.7%. 
Together these results support a role for miRNA in modulating EndMT.21 
miR-133a is another inhibitor of EndMT in vivo as transgenic mice that upregulate 
miR-133a specifically in heart were shown to be partially protected from EndMT seen 
in diabetic cardiac fibrosis.49 Similarly, overexpression of miR-200b in endothelial 
cells reduced cardiac fibrosis in diabetic mice and prevented EndMT. Interestingly, 
the downregulation of miR-200b seen in diabetic hearts compared to controls 
occurred only in endothelial cells, not cardiomyocytes, further supporting 
involvement in the process of EndMT.43 
Consistent with findings in lung that miR-21 levels increase in pulmonary fibrosis,44 
Kumarswamy et al.46 saw the same trend in hearts that had undergone TAC. 
Furthermore, administration of miR-21 inhibitors was shown to reduce the proportion 
of cells undergoing EndMT supporting a function of miR-21 in activating EndMT.46 
Human studies 
Human studies on the involvement of microRNA in EndMT during fibrosis of heart, 
lung and kidney remain sparse. EndMT has been shown to occur in heart and kidney 
CAD, as discussed earlier, but these studies did not investigate changes in 
miRNA.20,21 Others have found differential expression of miRNAs in human fibrotic 
disease but not identified a direct link with EndMT.31,48 
MiRNA levels have been shown to correlate with disease states. A strong correlation 
was shown between miR-126a-5p serum levels and severity of disease in neonates 
with pulmonary hypertension.31 Likewise, miR-2150,51 have been demonstrated to 
increase with decreasing GFR in renal transplantation whereas miR-200b51 falls. In 
Kawasaki disease there was an inverse correlation between serum levels of miR-483 
and severity of disease. Interestingly, it seems that miR-483 comes from endothelial 
cells as there was also an inverse correlation between CD31-positive microparticles 
containing miR-483 and degree of coronary artery damage.48 Certain miRNAs, 
previously shown to have a role in EndMT through in vitro or animal studies, have 
also been implicated in the process of graft rejection in humans and so it could be 
hypothesized that these they miRNA changes affect endothelial function.  
For instance, miR-21 and miR-155 have been found to be upregulated in human 
cardiac allograft rejection. Admittedly, in this study the focus was on acute rejection 
with biopsies taken within a year of transplantation. Also in the case of miR-21 the 
upregulation was only significant when comparing tissue showing severe rejection 
with control biopsies taken from native heart to investigate unexplained ventricular 
tachyarrhythmias rather than non-rejecting transplants. However, miR-155 was 
significantly upregulated in rejecting vs non-rejecting cardiac transplant biopsies and 
levels were found to parallel rejection severity.52  
miR-21 has also been implicated in lung allograft rejection as although it was not 
detected in normal human lung it was shown to be strongly expressed in chronic 
rejection, particularly in fibroblasts and epithelial cells in affected areas.53 
In kidney transplantation, of the miRNAs already discussed as playing a role in 
EndMT, it is miR-21, miR-200b and miR-155 for which there is most evidence to 
support a function in kidney CAD. Analysis of urine samples from living donor renal 
transplant recipients with proven rejection on biopsy showed increased levels of 
miR-21 and decreased levels of miR-200b when compared with healthy controls. 
However, in the case of miR-21 this difference did not maintain significance when 
those with rejection were compared to those with stable graft function,50,51 which is 
similar to the picture seen in heart.52  
In keeping with previous findings of miR-155 being upregulated in EndMT,41,45 levels 
in blood samples were significantly higher in patients with renal allograft rejection 
compared to those with stable graft function or healthy controls.50  
How MicroRNAs regulate EndMT in fibrosis 
Modulating expression of specific miRNAs can impact on EndMT and has been used 
to investigate their function. Current knowledge on the ways in which miRNAs 
interact with the pathways regulating EndMT in fibrosis are summarized in Figure 2 
with more detail provided in Table 3. Various mechanisms of action have been 
implicated and miRNAs may be effective at modulating EndMT only within a precise 
time window. For instance, miR-20a mimics reduced the number of cells that entered 
EndMT in vitro but had no effect on cells that had already started the program.22 
A positive feedback loop has been demonstrated between miR-29, let-7 and FGFR1 
which functions to inhibit TGFβ signaling.21 Another example of a positive feedback 
loop is found in the interaction between miR-130a and NFκB. miR-130a is 
upregulated in a NFκB dependent fashion in both fibrotic mouse lungs and cells 
treated with TGFβ1 in vitro. MiR-130a mimics were found to increase NFκB-linked 
luciferase activity whereas antagomirs decreased it indicating a function in promoting 
NFκB expression. As miRNAs primarily inhibit gene expression it is possible that 
there are other steps downstream of miR-130a leading to promotion of NFκB 
expression.54  
In the case of miR-145, a reciprocal inhibitory interaction exists with the long non-
coding RNA MALAT1 which is upregulated downstream of TGFβ and acts to reduce 
production of mature miR-145.40 
For other miRNAs there is more conflicting data on their modes of action. miR-155 
appears to function as a negative regulator of EndMT as it is upregulated by fibrotic 
stimuli but inhibits EndMT when overexpressed and prevents the activation of RhoA 
downstream of TGFβ when studied in mouse embryonic endothelial cells.41,45 
Furthermore, miR-155 has been found to directly target TGFβ inhibitor c-Ski mRNA 
to inhibit its expression and so disinhibit TGFβ signaling, consistent with inhibiting 
EndMT.41 However, this may be a tissue specific role as it is not in keeping with 
findings in human and mouse heart transplantation where, although miR-155 was 
similarly upregulated with fibrosis, graft survival was increased in miR-155 knockout 
mice so supporting a function of miR-155 to promote fibrosis.52 In vitro work on 
human coronary artery endothelial cells found miR-155 to promote EndMT as the 
addition of its inhibitor hindered TGF-β induced changes in markers.41   
Studies differ in their findings of whether PI3K activity is increased or decreased in 
EndMT but miRNAs have been shown to interact with this level of the pathway 
nonetheless.29,31,46 Kumarswamy et al.,46 suggest that the proportion of p-Akt is 
increased on activation of TGFβ signaling through direct downregulation of the 
inhibitor PTEN by miR-21. Treatment of cells with pre-miR-21 alone was able to 
induce the gene expression changes seen in EndMT of CD31 and eNOS 
downregulation and MMP2 and MMP9 upregulation.46 In work by Xu et al.,31 the 
proportion of p-Akt in endothelial cells was reduced in hypoxia but could be rescued 
by inhibition of miR-126a-5p which is upregulated under such conditions. However, 
the targets of this miRNA were not elucidated in this study as levels of PI3K 
remained stable and although miR-126a-5p shares 8 complementary bases with the 
TGFβ2 gene, again it was unable to significantly affect expression.31 Zhang et al.,29 
similarly found PI3K activity to be reduced in response to TGFβ1 and attributed this 
to an increase in inhibition from PI3KR2. The reduction in miR-126 seen in these 
conditions was thought to be the effector for this change as PI3KR2 was found to be 
one of its direct targets. Furthermore, overexpressing miR-126 prevented this 
reduction in the proportion of p-Akt associated with TGFβ1 treatment.29 
 
 
 
Clinical relevance 
Some studies have demonstrated that existing treatments for diseases associated 
with fibrosis influence miRNA expression and so inhibit EndMT.48,55,56 Specifically, 
atorvastatin was shown to act on the KLF4-miR-483-CTGF axis in Kawasaki’s 
Disease48 and the downregulation of miR-29 and let-7 observed in the diabetic 
mouse kidney was prevented by linagliptin56 and imidapril55 respectively. However, 
this body of research does not extend into the realms of allograft rejection.  
MiRNA levels can be manipulated in vivo21,46  to effectively alter a disease process. 
Expression can be increased with synthetic miRNA mimics57 or vectors carrying a 
pre-miRNA sequence.58 miRNA blockade is achieved with antagomirs (chemically 
modified antisense oligonucleotide sequences to a particular miRNA), miRNA 
sponge59 to competitively bind miRNAs or miRNA mask60 to competitively bind the 
target sequence. Promising progress is being made in the area of HCV where a miR-
122 inhibitor (Miravirsen) effectively reduced HCV RNA levels beyond the duration of 
treatment in a phase II clinical trial, without developing viral resistance.61 Drugs 
targeting miRNAs to treat cancer have also reached clinical development.62 
Aside from therapeutics, understanding changes in miRNA levels could contribute to 
clinical care through diagnosis and monitoring of disease. At this stage, only a 
handful of papers discuss the potential for using miRNAs as biomarkers in CAD37,63-
69 but there is more work on acute allograft rejection.  The stable nature of miRNAs 
make them an attrctive target to investigate as biomarkers. So far this quality has 
facilitated their study in various samples including tissue, urine, serum and plasma.69  
It is worth considering also the implications of losing endothelial cell phenotype 
through EndMT, rather than purely the gain of mesenchymal features as contributing 
to the disease process. A logical consequence of endothelial cells losing their 
phenotype in this way would be a reduction in the density of capillaries. Particularly 
in the kidney, capillary rarefaction is one of the main features of progressive fibrotic 
disease70,71 in both native and transplanted organs. In targeting EndMT it may 
therefore be possible to reduce both gain of fibrotic tissue and loss of capillaries in 
order to improve organ function.  
Concluding remarks and future perspectives 
The predominant preclinical model used for fibrosis is diabetes (Table 2) and more is 
required at the preclinical level to specifically look at the process of CAD. Although 
levels of some miRNAs have been shown to be altered in serum,48 other studies 
have suggested an autocrine or paracrine action.43 If local mechanisms of action do 
predominate, a more invasive approach to human studies would be required using 
tissue samples rather than serum to detect changes.  
Given the dearth of research into microRNA regulation of fibrosis in human CAD a 
key next step would be to investigate whether findings from animal models reliably 
translate into humans. As summarized in Tables 1 and 2 there is some variability in 
miRNA expression changes between in vitro and in vivo models depending on cell 
types used; particularly in the case of the let-7 which is perhaps the most widely 
studied miRNA in this field. It is therefore essential to correlate findings from 
preclinical models to those in human disease. Ultimately the goal should be for a 
better understanding of miRNA in fibrosis to enable early detection and treatment of 
CAD so improving transplant survival and patient quality of life. 
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MiRNAs Upregulated Downregulated 
let-7 Mouse cardiac endothelial cells28 
 
Mouse transplanted aorta21  
Mouse diabetic kidney55 
HUVEC21 
HUAEC21 
HMEC27 
18a-5p  HAVEC47 
Mouse diabetic heart47 
20a  HUVEC22 
21 Irradiated mouse lung44 
Human pulmonary endothelial 
cells44 
HUVEC34,46 
Mouse cardiac endothelial cells28 
Mouse TAC operated hearts46  
 
29  HUVEC46 
HMVEC27,56 
Mouse diabetic kidney27,56 
30b Mouse cardiac endothelial cells28  
122a  Mouse cardiac endothelial cells28 
125b Mouse cardiac endothelial cells28  
126 Chronic hypoxic rat lung31 
RPMEC31 
EPC29 
127  Mouse cardiac endothelial cells28 
 Table 1: miRNAs identified to be upregulated or downregulated in EndMT in 
different studied cells and tissues 
130a Lung microvascular endothelial 
cells54  
 
133a  Mouse diabetic heart49 
155 MEEC45, HCAEC41  
195 Mouse cardiac endothelial cells28  
196  Mouse cardiac endothelial cells28 
200a  HAEC23 
200b  Mouse diabetic heart 43 
Primary mouse heart endothelial 
cells43 
216a HUVEC46  
320  HUVEC42 
375  Mouse cardiac endothelial cells28 
483  HUVEC48 
 Fibrosis model MiRNAs  
Transplantation  Mouse Down: Let-721 (aorta)  
Transverse aortic 
constriction 
Mouse Up: miR-2146 (heart) 
Diabetes Mouse Down: miR-200b43 (heart), miR-18a-5p47 
(heart), miR-133a49, let-727,55 (kidney), 
miR-2927,56 (kidney),  
Rat Down: miR-32042 (kidney) 
Radiation Mouse Up: miR-2144 (lung) 
Monocrotaline-induced 
pulmonary hypertension  
Rat Up: miR-130a54 (lung) 
Chronic hypoxia-induced 
pulmonary hypertension 
Rat Up: miR-126a-5p31 (lung) 
 
Table 2 Differentially expressed miRNAs in EndMT in different in vivo animal 
models of fibrosis  
Upregulated Up. Downregulated Down. Tissue studied in brackets. 
 
MiRNA Factors modulating 
miRNA levels  
Actions of miRNA on pathway 
FGF and TGFβ 
let-721,27 Upregulated by FGF 
signaling which is inhibited 
by TNFα, IFNϒ and IL1β in 
fibrosis 
Direct inhibition of TGFβR1 
expression21 
upregulates FGFR1 and miR-2927 
miR-20a22  
 
Upregulated by FGF 
signaling 
Inhibits TGFβ signaling: directly 
targets ALK5 (TGFβR1), TGFβR2 
and SARA 
miR-2927 Upregulated by FGFR1 
signaling  
Directly inhibits IFNϒ expression 
Upregulates FGFR1 and let-7 
miR-133a49  Inhibits expression of endothelin-1 
which acts synergistically with TGFβ.  
Prevented TGFβ-induced increased 
in pSmad2 and pERK1/2 expression.  
miR-14540 TGFβ1 signaling reduces 
processing of pre-miR-145 
into mature form by 
upregulating MALAT1 which 
inhibits DICER expression  
Directly inhibits MALAT1 expression 
and TGFβR2 and Smad3 expression 
to inhibit TGFβ signaling 
Ras/RhoA 
miR-200a23 Downregulated by TGFβ 
signaling 
Directly inhibits growth factor 
receptor bound protein 2 (GRB2) 
expression. GRB2 is downstream of 
TGFβ and activates Ras to GTP-
bound form. 
NFκB 
miR-130a54 Upregulated by NFκB 
downstream of TGFβ 
Promotes NFκB expression so part 
of a positive feedback loop  
PI3K 
miR-2146  Directly inhibits PTEN, an inhibitor of 
PI3K, to increase PI3K activity 
downstream of TGFβ. 
Downregulated CD31 and eNOS and 
upregulated MMP2 and MMP9. 
miR-126a-
5p31 
 Prevents fall in proportion of 
phosphorylated Akt seen in hypoxia. 
Exact target is not known. 
miR-12629 Downregulated by TGFβ1 
signaling 
Prevents TGFβ-induced fall in 
proportion of phosphorylated Akt by 
directly inhibiting expression of 
PI3KR2, a PI3K inhibitor. 
DPP-4 
miR-2956  Directly inhibits DPP-4 expression 
Acetylation 
miR-133a49  Prevents upregulation of the 
acetylating transcription coactivator 
P300 
miR-200b43  Prevents upregulation of the 
acetylating transcription coactivator 
P300 
Angiotensin 
Let-755 Levels restored by 
increasing AcSDKP directly 
or through administration of 
ACE inhibitor 
 
miR-133a49  Prevents increase in 
angiotensinogen mRNA expression 
Notch 
miR-18a-
5p47 
 Directly inhibits Notch2 expression 
KLF/CTGF 
miR-18348 Upregulated by KLF which 
is downregulated in 
inflammation 
Directly inhibits CTGF (connective 
tissue growth factor) expression 
 
Table 3 Actions of miRNAs on pathways implicated in regulation of EndMT 
Pathways indicated by subtitles. MiRNAs that are downregulated in EndMT or fibrosis are listed in italics, those that are 
upregulated are in normal script. The second column lists factors and pathways that have been shown to influence miRNA 
expression. miRNAs affecting FGF and TGFβ signaling pathways have been grouped together as a reciprocal inhibitory 
interaction exists between these two pathways which is at least partly mediated by interaction with miRNAs.21,22,27  
Figure 1 Allograft injury results in release of cytokines, chemokines and increase in 
inflammatory and immune cells in the allograft which induce differentiation of different 
cells, including tissue-resident fibroblasts15, bone marrow progenitor cells14, 
endothelial cells14,18,24,72,73, epithelial cells74,75 and pericytes76, into myofibroblasts. 
Myofibroblasts produce collagen and collagen deposition results in fibrosis associated 
with chronic allograft failure.6,11,77  
Figure 2 Summary of main signalling pathways involved in changing gene expression 
in EndMT and how microRNAs that are upregulated (orange) or downregulated 
(purple) interact with these pathways. Red arrows indicate inhibition. Green arrows 
indicate activation.7,9,21-23,27-29,31,34,41-49,54-56,78  
Figure 3 In the nucleus, the miRNA gene is transcribed by RNA polymerase II into the 
double stranded hairpin-shaped pri-miRNA.79,80 The enzyme Drosha RNase III 
endonuclease works with cofactor DGCR8 (DiGeorge syndrome critical region 8) to 
cleave both strands of pri-miRNA near the base of the primary stem loop to produce 
a shorter 60-70 nucleotide hairpin-shaped precursor known as pre-miRNA79,80 Pre-
miRNA is then actively exported into the cytoplasm via Exportin5 channel. Here, a 
second RNase III endonuclease, Dicer, cuts both strands of pre-miRNA near the base 
of the stem loop to leave a duplex of the mature miRNA and a similar sized 
complementary fragment of the opposing arm (miRNA*). The duplex is separated by 
incorporation of miRNA strand into RNA-induced silencing complex (RISC) by binding 
to argonaute proteins38,79,81  
